MarketPR

Lantern Pharma closes $4 million registered direct offering

9/30/2026

(NASDAQ: LTRN) closed a registered direct offering on September 30, 2026, selling 3,669,725 shares of common stock or pre-funded warrants at $1.09 per unit.

The company stated that the aggregate gross proceeds from this transaction were approximately $4 million before deducting placement agent fees and other offering expenses.

In a concurrent private placement, Lantern issued unregistered warrants to purchase up to 3,669,725 additional shares of common stock.

These warrants carry an exercise price of $1.09 per share and will expire five years after receiving stockholder approval for the underlying share issuance.

Keep reading

Read the full story

Open on MarketPR